Navigation Links
DRAXIS Announces Completion of Sale to Jubilant

TORONTO, May 28 /PRNewswire-FirstCall/ - DRAXIS Health Inc. ("DRAXIS") (TSX: DAX) (NASDAQ: DRAX) announced today the completion of the statutory arrangement under which all of DRAXIS' common shares have been acquired by an indirect wholly-owned subsidiary of Jubilant Organosys Ltd. for US$6.00 per common share. As a result, DRAXIS common stock is expected to cease trading on the NASDAQ Global Market and on the Toronto Stock Exchange at market close on Thursday, May 29, 2008, and will no longer be listed on these stock exchanges.

Payment of the cash consideration will be made by Computershare Investor Services.

DRAXIS shareholders who possess physical stock certificates have received instructions and a letter of transmittal by mail from Computershare Investor Services concerning how and where to forward their certificates for payment. For shares held in "street name" by a broker, bank or other nominee, shareholders will not need to take any action to have shares converted into cash, as this will be carried out by the broker, bank or other nominee. Questions about the payment of proceeds should be directed to the appropriate broker, bank or other nominee.

About DRAXIS Health Inc.:

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its Montreal facility.
For additional information please visit

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- the achievement of desired clinical trial results related to DRAXIS'

pipeline products;

- timely regulatory approval of DRAXIS' products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of DRAXIS' products;

- DRAXIS' ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

DRAXIS and its products;

- factors beyond DRAXIS' control that could cause interruptions in

operations in its single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- DRAXIS' dependence on a small number of key customers;

- the disclosure of confidential information by DRAXIS' collaborators,

employees or consultants;

- the preservation of healthy working relationships with DRAXIS' union

and employees;

- DRAXIS' ability to grow the business;

- the fluctuation of DRAXIS' financial results and exchange and

interest rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against DRAXIS succeed;

- the volatility of the price of DRAXIS' common shares;

- market acceptance of DRAXIS' products;

- factors described under "Outlook" in DRAXIS' MD&A for the most recent

quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in

the Annual Report Form 20-F filed by DRAXIS with the United States

Securities and Exchange Commission and which is also filed as

DRAXIS' Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other factors, and relating to DRAXIS generally, reference is made to DRAXIS' most recent filings with the United States Securities and Exchange Commission (available on EDGAR at and the filings made by DRAXIS with Canadian securities regulators (available on SEDAR at The forward-looking statements contained in this document represent DRAXIS' expectations as at May 27, 2008. Unless otherwise required by applicable securities laws, DRAXIS disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DRAXIS Obtains Final Order for Proposed Arrangement
2. DRAXIS Health Reports Results for the First Quarter of 2008
3. DRAXIS to Report First Quarter Results on May 9th
4. DRAXIS Obtains Interim Order for Proposed Arrangement
5. Jubilant to acquire Draxis Health
6. DRAXIS Responds to Trading
7. DRAXIS Health Reports Fourth Quarter and Year End Results
8. DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th
9. DRAXIS Share Buyback Approved by TSX
10. DRAXIS Announces Application for Normal Course Issuer Bid
11. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving (MADD) ... below 10,000 for the first time since 2011. In 2014, there were 9,967 fatalities ... released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
Breaking Medicine Technology: